Xác định đột biến gen EGFR ở bệnh nhân ung thư phổi không tế bào nhỏ

Targeted therapy is a novel and promising treatment method for non-small cell lung cancer (NSCLC). However, the response was demonstrated only in EGFR - mutated NSCLC patients. The objectives of the study were identifying EGFR mutations in NSCLC patients by sequencing and Scorpion ARMS methods and comparing sequencing and Scorpion ARMS techniques in identifying EGFR mutations of NSCLC. 70 NSCLC patients were selected for this study, using sequencing and Scorpion ARMS technique to identify EGFR mutations. The results showed that 28/70 (38.6 percent) NSCLC patients have EGFR mutations in exon 18, 19, 20 and 21; the frequency G719S mutation (exon 18), LREA deletion (exon 19) and L858R (exon 21) were 3.7 percent, 51.9 percent and 37 percent, respectively. Two novel mutations were detected by sequencing (3.7 percent). In conclusion, identifying of EGFR mutations in NSCLC by sequencing and Scorpion ARMS has the same results in most of the cases. Sequencing detected 2 novel mutations.